Based on recent work on the TPr/TXA2 axis in cancer metastasis, it appears likely that the antimetastatic efficacy of ifetroban is also due at least in part to changes in tumor angiogenesis/endothelial function and immune modulation. Here, TPR is linked to neoplasm.